Health Blueprint

Back to Longevity News

News summary

IBio’s primate data hint at muscle-sparing obesity add-on

Source: Longevity Technology • Published: 29 Oct 2026, 17:43

Summarized by Masters of Longevity from Longevity Technology.

Single-dose IBIO-610 cut Activin E and shifted weight loss toward fat in obese NHPs.

IBio’s primate data hint at muscle-sparing obesity add-on
Key Takeaways
  • A single IBIO-610 dose nearly eliminated active Activin E in monkeys.
  • IBIO-610 plus semaglutide shifted observed weight loss to fat.
  • The antibody had a 33.2-day half-life in the primate study.
Read the full article at Longevity Technology ↗

Continue exploring

Recommended MoL Picks

MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?MoL PickReducing Inflammation from Ageing Cells: What a Mouse Study FoundResearchers reduced the inflammatory signals released by cells that had stopped dividing. Older mice also improved on some strength and frailty tests. Whether this approach could help people remains unknown.